Topics

This didn't get a lot of looks due to the CMO departure news but it's the largest in-licensing deal ever for an asset in China. $65M up front - pretty good dough that should be a wake up call for any companies that don't have a China plan yet. https://glo

16:29 EDT 29 Apr 2019 | Brad Loncar

This didn't get a lot of looks due to the CMO departure news but it's the largest in-licensing deal ever for an asset in China. $65M up front - pretty good dough that should be a wake up call for any companies that don't have a China plan yet. https://globenewswire.com/news-release/2019/04/29/1811184/0/en/Immunomedics-and-Everest-Medicines-Announce-Exclusive-License-Agreement-for-Sacituzumab-Govitecan-in-East-and-Southeast-Asia-Excluding-Japan.html …

Original Article: This didn't get a lot of looks due to the CMO departure news but it's the largest in-licensing deal ever for an asset in China. $65M up front - pretty good dough that should be a wake up call for any companies that don't have a China plan yet. https://glo

NEXT ARTICLE

More From BioPortfolio on "This didn't get a lot of looks due to the CMO departure news but it's the largest in-licensing deal ever for an asset in China. $65M up front - pretty good dough that should be a wake up call for any companies that don't have a China plan yet. https://glo"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...